Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Alfred J Novak is Director at Pasithea Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on May 5, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
May 1, 2026153Kdisclosed May 5
DetailsOfficial recordAlfred J Novak bought shares on the open market in 2020, and has not bought since 2020. Sales in 5 of the 11 years since 2016.
Alfred J Novak reported 1 open-market purchase and 9 sales since 2016; purchases in 2020.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $267K2×2 trades |
| 2020 | $47K1×1 trade | — |
| 2019 | — | $92K1×1 trade |
| 2018 | — | $237K3×3 trades |
| 2017 | — | $230K2×2 trades |
| 2016 | — | $204K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Alfred J Novak reported 1 open-market purchase and 9 sales here, 2016 to 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Alfred J Novak bought shares on the open market in 2020, and has not bought since 2020. Sales in 5 of the 11 years since 2016.
In SEC filings since 2016: the latest open-market purchase is from 2020; the latest open-market sale is from 2021.
LivaNova (LIVN), from 2016 to 2021: 1 purchase and 9 sales.